Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04209465 · ClinicalTrials.gov registry record · Phase 1
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
A Phase 1 study, sponsored by Black Diamond Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT04209465 is a Phase 1 study that was terminated before completion, run by Black Diamond Therapeutics. The registered enrollment target is 91 participants.
The verdict
NCT04209465, a Phase 1 study, was terminated before completion, sponsored by Black Diamond Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study were to: * Find the recommended dose of BDTX-189 that can be given safely to participants * Learn more about the side effects of BDTX-189 * Learn what the body does to BDTX-189 after it has been taken (pharmacokinetics or PK) * Determine the preliminary antitumor activity of BDTX-189 in participants with select allosteric ErbB gene mutations
Interventions
- DRUG BDTX-189
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2022-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04209465
The ClinicalTrials.gov registry entry for NCT04209465 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Black Diamond Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BDTX-189 is the first listed.
NCT04209465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04209465 about?
NCT04209465 is a clinical study titled "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.". This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study were ...
What is the current status of trial NCT04209465?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2019-12-19. Estimated completion is 2022-09-16.
What interventions are being tested in trial NCT04209465?
The interventions under investigation include: BDTX-189 (DRUG).
Who is sponsoring clinical trial NCT04209465?
This trial is sponsored by Black Diamond Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.